Breaking Finance News

JMP Securities upgraded Arena Pharmaceuticals (NDAQ:ARNA) from Mkt Perform to Mkt Outperform in a report released today.

Yesterday Arena Pharmaceuticals (NDAQ:ARNA) traded 1.84% higher at $19.10. The company’s 50-day moving average is $21.42 and its 200-day moving average is $15.97. The last stock close price is up 31.65% from the 200-day moving average, compared to the S&P 500 which has increased 0.05% over the same time. 596,252 shares of the stock were exchanged, down from an average trading volume of 1,079,330

JMP Securities has upgraded Arena Pharmaceuticals (NDAQ:ARNA) from Mkt Perform to Mkt Outperform in a report released on 07/07/2017.

Previously on Tuesday July 04, 2017, Cantor Fitzgerald reported about Arena Pharmaceuticals (NDAQ:ARNA) raised the target price from $0.00 to $37.00. At the time, this indicated a possible upside of 1.12%.

Performance Chart

Arena Pharmaceuticals (NDAQ:ARNA)

With a total market value of $0, Arena Pharmaceuticals has with a one year low of $11.30 and a one year high of $27.86 .

More About Arena Pharmaceuticals (NDAQ:ARNA)

Arena Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing small molecule drugs across a range of therapeutic areas. The Company has three primary investigational clinical programs: etrasimod (APD334) in Phase II evaluation for ulcerative colitis, APD371 entering Phase II evaluation for the treatment of pain associated with Crohn's disease, and ralinepag (APD811) in Phase II evaluation for pulmonary arterial hypertension (PAH). The Company's drug, Lorcaserin, is approved for marketing in the United States and South Korea for the indication of weight management. The Company's drug candidates in clinical development include APD334 for autoimmune diseases, ralinepag for vascular diseases and APD371 for pain. The Company's programs under collaboration include nelotanserin for dementia-associated psychosis, temanogrel for thrombotic diseases, and an undisclosed orphan GPCR for central nervous system (CNS) indication(s).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.